US 11,911,454 B2
Effective vaccination against porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
Jay Gregory Calvert, Otsego, MI (US); Robert G. Ankenbauer, Portage, MI (US); Jacqueline Gayle Marx, Portage, MI (US); Douglas S. Pearce, Kalamazoo, MI (US); and Marcia L. Keith, Plainwell, MI (US)
Assigned to Zoetis Services LLC, Parsippany, NJ (US)
Filed by Zoetis Services LLC, Parsippany, NJ (US)
Filed on Jun. 6, 2022, as Appl. No. 17/832,956.
Application 17/832,956 is a continuation of application No. 16/822,830, filed on Mar. 18, 2020, granted, now 11,351,244.
Application 16/822,830 is a continuation of application No. 13/895,564, filed on May 16, 2013, granted, now 10,610,581, issued on Apr. 7, 2020.
Claims priority of provisional application 61/648,461, filed on May 17, 2012.
Prior Publication US 2022/0296699 A1, Sep. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55 (2013.01); A61K 2039/552 (2013.01); C12N 2770/10034 (2013.01); C12N 2770/10064 (2013.01)] 12 Claims
 
1. A method for inducing a protective immune response in a porcine animal against infection by a Porcine Reproductive and Respiratory Syndrome (PRRS) virus, the method comprising administering to said animal a vaccine comprising a modified live PRRS virus, and a carrier suitable for veterinary use, wherein said vaccine is administered to said animal prior to weaning; wherein said vaccine is safe and immunoprotective even if administered when said animal is no more than two weeks of age; wherein said modified live PRRS virus is prepared by attenuating a virulent PRRS virus in a permissive mammalian cell line that exogenously expresses porcine CD163 receptor protein, and recovering virus from the culture; and wherein said protective immune response provides a reduction in mortality in comparison to an unvaccinated animal infected with PRRS.